GH 39 015
Alternative Names: GH-39-015Latest Information Update: 17 Feb 2023
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Feb 2023 Discontinued for Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, February 2023)
- 22 Jun 2022 GH 39 015 is available for licensing as of 22 Jun 2022. https://www.genhousebio.com/en/cooperation/index.html
- 22 Jun 2022 Early research in Cancer in China (unspecified route) (Suzhou Genhouse Bio pipeline, June 2022)